Why invest?

Drug development has the potential to discover and develop the next ‘blockbuster’ drug with the consequent high levels of revenue and corresponding company valuation, albeit, it is, by its very nature, a high risk based investment opportunity.

The company’s strategy to acquire, prepare and commercialise oncology assets at the earliest opportunity for licensing, purposefully de-risks the traditional drug development model.

This is achieved through the expertise within the team, it’s access to IP and its commercial and academic relationships, including a 10 year pipeline deal with the ICT at Bradford University, securing first rights to new oncology IP from the ICT.

This strategy is aimed at maximising the return of investment to shareholders, whilst minimising the investment required.